- Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
- Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
- Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
- Stoke Therapeutics Announces Proposed Public Offering
- Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
More ▼
Key statistics
On Thursday, Stoke Therapeutics Inc (STOK:NSQ) closed at 11.69, -28.72% below its 52-week high of 16.40, set on Mar 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.66 |
---|---|
High | 11.98 |
Low | 11.45 |
Bid | 11.34 |
Offer | 12.47 |
Previous close | 11.56 |
Average volume | 920.15k |
---|---|
Shares outstanding | 52.12m |
Free float | 49.73m |
P/E (TTM) | -- |
Market cap | 602.48m USD |
EPS (TTM) | -2.38 USD |
Data delayed at least 15 minutes, as of May 02 2024 21:00 BST.
More ▼